You are here
Profiles and Perspectives
Stem Cells Trans Med 2015; 4:413-418; doi:10.5966/sctm.2015-0052
This study developed a new model for evaluating an induced pluripotent stem cell (iPSC) haplobank based on demographic and immunogenetic characteristics reflecting California. Creation of a haplobank of iPSC lines homozygous for a variety of human leukocyte antigen (HLA) types, representative of different geographic populations and ethnic groups, could simplify HLA matching and provide matches for reasonable percentages of target populations and extend iPSC-derived therapies beyond the autologous setting.
Stem Cells Trans Med 2015; 4:419-423; first published on March 13, 2015; doi:10.5966/sctm.2014-0224
The importance of fetal microchimerism to the field of fetal stem cell biology and issues of maternal contamination from perinatal tissues is highlighted and specific isolation strategies to overcome these translational obstacles are discussed.
Stem Cells Trans Med 2015; 4:207-210; first published on January 30, 2015; doi:10.5966/sctm.2014-0276
Liver cell transplantation holds potential for the treatment of liver failure, end-stage liver disease, and liver-based inborn errors of metabolism; however, the field is in search of a suitable cell therapeutic.
Stem Cells Trans Med 2015; 4:211-216; first published on February 2, 2015; doi:10.5966/sctm.2014-0299
In late 2006, the California Institute for Regenerative Medicine (CIRM) launched its first major research initiative to catalyze the nascent field of human embryonic stem cell (hESC) research. The Scientific Excellence through Exploration and Development (SEED) program attracted new investigators from all stages of their career to the field of hESC research.
Stem Cells Trans Med 2015; 4:217-223; first published on February 3, 2015; doi:10.5966/sctm.2014-0233
This article discusses the need for reference materials, potential challenges faced by human pluripotent stem cell-derived products, and possible approaches to alleviating concerns about consistency and reproducibility in their production.
Stem Cells Trans Med 2015; 4:118-122; first published on December 29, 2014; doi:10.5966/sctm.2014-0144
The current lack of training for physicians in cell-based therapy combined with the sharply increasing practice of regenerative medicine is concerning for a number of reasons, namely potential harm to patients and avoidable conflicts between governmental regulatory agencies and physicians.
Stem Cells Trans Med 2015; 4:123-129; first published on January 5, 2015; doi:10.5966/sctm.2014-0192
The Deriving Induced Stem Cells Using Stored Specimens (DISCUSS) project is a consensus-building initiative designed to consider how human somatic cells obtained under general biomedical research protocols can be used in induced pluripotent stem cell (iPSC) derivation.
Stem Cells Trans Med 2015; 4:130-135; first published on January 9, 2015; doi:10.5966/sctm.2014-0254
The 2014 Regenerative Medicine Foundation Annual Conference had a vision of assisting with translating tissue engineering and regenerative medicine-based technologies by assembling leaders in the field to cover critical areas, including regulatory pathways for regenerative medicine therapies, strategic partnerships, resource coordination, developing standards, government support, industry priorities, biobanking, and new technologies.
Stem Cells Trans Med 2014; 3:1393-1397; first published on November 6, 2014; doi:10.5966/sctm.2014-0221
Debilitating eye diseases such as age-related macular degeneration and retinitis pigmentosa currently represent a large unmet medical need that could potentially be addressed by stem cell therapy.
Stem Cells Trans Med 2014; 3:1398-1401; first published on October 8, 2014; doi:10.5966/sctm.2014-0147
This study examines the major ethical and social questions raised by the cancellation of the 2010 phase I clinical trial of a human embryonic stem cell-based therapy for spinal cord injury. The study provides recommendations for institutional review boards and clinical sites as they deliberate approvals of early-phase trials in frontier medicine.